Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 9NIH 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4CNS 4NET 3Gastrointestinal 1

Conditions

Neoplasms 805Carcinoma, Non-Small-Cell Lung 767Breast Neoplasms 731Neoplasm Metastasis 340Colorectal Neoplasms 339Prostatic Neoplasms 324Multiple Myeloma 309Melanoma 305Recurrence 237Ovarian Neoplasms 236Leukemia, Myeloid, Acute 236Lymphoma, Non-Hodgkin 213Lung Neoplasms 211Carcinoma, Renal Cell 200Lymphoma 189Lymphoma, Follicular 163Pancreatic Neoplasms 157Leukemia, Lymphocytic, Chronic, B-Cell 149Carcinoma, Hepatocellular 140Stomach Neoplasms 137Leukemia 133Head and Neck Neoplasms 128Lymphoma, Large B-Cell, Diffuse 126Parkinson Disease 4, Autosomal Dominant Lewy Body 119Squamous Cell Carcinoma of Head and Neck 110Urinary Bladder Neoplasms 109Carcinoma 101Small Cell Lung Carcinoma 99Triple Negative Breast Neoplasms 97Glioblastoma 96

Interventions

3-Iodobenzylguanidine 2lutetium Lu 177 dotatate 1copper dotatate CU-64 1Nivolumab 1Lutetium-177 1Lutetium 1Iodine-131 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Paraganglioma × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT04187404 2026-01-30

Spencer

Enterome

Phase 1/2 Terminated
70 enrolled 20 charts
CNSEndocrine

Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡